rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    CANF
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Can-Fite Pivotal Phase III Psoriasis Study Under an FDA- and EMA-agreed protocol: All Patients Completed Dosing and Interim Analysis Expected Q1 2027

      The study evaluates oral Piclidenoson and last patient in the interim-analysis cohort completes treatment  Ramat Gan, Israel, Nov. 18, 2026 (GLO...

      16h agoBusiness InsiderCANF
      12 Health Care Stocks Moving In Wednesday's After-Market Session
      Nov 11BenzingaCANF
      Can-Fite Reports Ten-Year Survival Milestone for Advanced Liver Cancer Patient from Phase II Namodenoson Study

      Patient from the Company’s completed Phase II study remains cancer-free and in good health at the ten-year survival milestone Ramat Gan, Israel, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced that a patient with advanced liver cancer who participated in its completed Phase II study of Namod

      Nov 9Yahoo FinanceCANF
      Can-Fite to Pursue Global Licensing and Strategic Partnerships at BIO-Europe 2026 Following Recent Clinical and Intellectual Property Milestones
      Nov 6Yahoo FinanceCANF
      Can-Fite Announces Eurasian Patent Allowance Supporting Piclidenoson Development and Commercialization in Lowe Syndrome

      Allowed claims cover Lowe syndrome and Dent disease 2; Can-Fite holds development, commercialization, and out-licensing rights for these indications under its agreement with Fondazione Telethon Ramat Gan, Israel, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced that the Eurasian Patent Office (EAPO) has is

      Nov 2Yahoo FinanceCANF
      Can-Fite Presents Final Positive Data from Phase IIa Pancreatic Cancer Study of Namodenoson at ESMO 2026
      Oct 26Yahoo FinanceCANF
      H.C. Wainwright reiterates Can-Fite BioPharma stock rating at buy
      Sep 29Investing.comCANF
      Can-Fite: Publication Reports Improvement in Decompensated Cirrhosis with Namodenoson and Successful Bridging to Liver Transplantation

      Patient Experienced Resolution of Ascites, Regression of Esophageal Varices and Remained Clinically Stable for Approximately 28 Months Prior to Successful Liver Transplantation Ramat Gan, Israel, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced the publication of a peer-reviewed case report

      Sep 9Yahoo FinanceCANF
      Can-Fite Reports Q2 2026 Financial Results and Ongoing Clinical Progress Highlighting Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study

      RAMAT GAN, Israel, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced clinical updates and financial results for H1 2026. Advances in Clinical Programs Pancreatic Cancer Phase 2a study evaluating Namodenoson in patients with advanced pancreatic ductal adenocarcinoma achieved its primary safety endpoint and d

      Sep 8Yahoo FinanceCANF
      Can-Fite BioPharma Evaluates Earlier Interim Analysis for Key Liver Cancer Study
      Sep 2Yahoo FinanceCANF
      Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds

      RAMAT GAN, Israel, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF) (“Can-Fite” or the “Company”), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 1,591,738 American Depositary Shares (ADSs), having an exercise

      Sep 2Yahoo FinanceCANF
      12 Health Care Stocks Moving In Wednesday's Pre-Market Session
      Sep 2BenzingaUPCCANF
      Can-Fite BioPharma Announces $4 Million Warrant Exercise

      Can-Fite BioPharma (CANF) agreed to the immediate exercise of warrants for up to about 1.6 million A

      Sep 2Yahoo FinanceCANF
      Can-Fite Reports Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study

      Company plans to advance the interim analysis of its Phase III Namodenoson study in advanced hepatocellular carcinoma Ramat Gan, Israel, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced that blinded overall survival observed across the entire patient population in its ongoing pivotal Phase I

      Sep 2Yahoo FinanceCANF
      Can-Fite BioPharma Files $100 Million Shelf

      Can-Fite BioPharma (CANF) filed a registration statement Friday with the U.S. Securities and Exchang

      Aug 28Yahoo FinanceCANF

      This is the newest page. Registered accounts read further back.